Abstract: The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

Abstract: Compositions and methods for the treatment of pulmonary conditions, especially pulmonary conditions characterized by persistent cough, are disclosed. The compositions and methods employ at least one muscarinic receptor antagonists and at least one local anesthetic administered pulmonarily either simultaneously or in sequence. The compositions may be in powder or liquid form.

Abstract: The invention relates to a method of treating a corticosteroid-responsive condition of the air passage ways and lungs by delivering a corticosteroid to the pulmonary system of a patient, comprising administering a particle mass comprising a corticosteroid from an inhaler characterized in that the corticosteroid is not substantially deposited in the mouth and throat and is not substantially systemically absorbed. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.

Abstract: A method and compositions for targeted drug delivery have been developed. The compositions include a targeting molecules such as a hormone that specifically binds to a receptor on the surface of the targeted cells; a drug to be delivered, such as a toxin that will kill the targeted cells; and a nanoparticle, which contains on or within the nanoparticle, the drug to be delivered, as well as has attached thereto, the targeting molecule. Nanoparticles can consist of drug or drug associated with carrier, such as a controlled or sustained release materials like a poly(lactide-co-glycolide), a liposome or surfactant. The compositions are administered by injections in most cases, although compositions can be applied topically orally, nasally, vaginally, rectally, and ocularly. Compositions can also be administered to the pulmonary or respiratory system, most preferably in an aerosol.

Abstract: Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The composition also include, or are administered in conjunction with, an enhancer in an amount effective to maximize expression of or binding to receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents. Compositions are applied topically orally, nasally, vaginally, rectally, and ocularly. The enhancer is administered with the composition or separately, either systemically or preferably locally. The compound to be delivered can also be the enhancer.

Abstract: Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.